Formation Bio raised $372MM in a Series D funding led by a16z with participation from Sanofi and other investors

Jun 26, 2024•over 1 year ago

Amount Raised

$372 Million

Round Type

series d

New YorkPharmaceuticalArtificial IntelligenceBiotechnologyHealth Care

Investors

Fpv VenturesSv Angel GrowthLachy GroomEmerson CollectiveThriveSequoiaSanofiA16z

Description

Formation Bio, a tech-driven and AI-native pharma company, raised $372MM in a Series D financing round. The funding was led by a16z with significant participation from Sanofi, along with other existing and new investors. The company aims to use the funding to grow its drug pipeline and continue expanding its AI-driven drug development platform.

Company Information

Company

Formation Bio

Location

New York, New York, United States

About

TrialSpark, a tech-driven drug developer with a portfolio of clinical stage drug assets, is rebranding to Formation Bio. Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends